Skip to content
My WebMD Sign In, Sign Up

Ovarian Cancer Health Center

Font Size

Changes to This Summary (08�/�02�/�2011)

continued...

Recurrent or Persistent Ovarian Epithelial Cancer Treatment

Added Rustin et al. as reference 2.

Added text to state that monitoring CA 125 levels in follow-up may play a role in identifying appropriate candidates for secondary cytoreduction, although this strategy awaits confirmation with a randomized trial.

Revised Table 7 title to read Regimens Used in First Relapse. Added PLD plus trabectedin to list of regimens used in first relapse. Added Monk et al. as reference 4.

Added text to state that in a phase III trial, carboplatin plus PLD (CD) was compared to carboplatin plus paclitaxel (CP) in patients with platinum-sensitive recurrence and a primary endpoint was progression-free survival (PFS) with a median PFS for the CD arm of 11.3 months versus 9.4 months for the CP arm (cited Pujade-Lauraine et al. as reference 13 and level of evidence 1iiDiii).

1|2
1|2

WebMD Public Information from the National Cancer Institute

Last Updated: May 16, 2012
This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.

Today on WebMD

what is your cancer risk
HEALTH CHECK
ovarian cancer overview slideshow
SLIDESHOW
 
cancer fighting foods
SLIDESHOW
15 Cancer Symptoms Women Ignore
FEATURE
 
Integrative Medicine Cancer Quiz
QUIZ
Lifestyle Tips for Depression Slideshow
SLIDESHOW
 
Screening Tests for Women
Slideshow
Graphic of ovaries within reproductive system
VIDEO
 
Ovarian Cancer Marker
VIDEO
Pets Improve Your Health
SLIDESHOW
 
Vitamin D
SLIDESHOW
Healthy meal with salmon
Article